ADVERTISEMENT
'Buy' Sun Pharma Maintains Systematix, Sees Checkpoint Acquisition To Strengthen Onco Derma Portfolio
Systematix retains estimates on Sun Pharma and retain Buy with a target price of Rs 2,206 based on 35 times FY27E earnings per share.
11 Mar 2025, 10:32 AM IST 
Sun Pharma's Checkpoint acquisition is valued at $355 million ($400 million including Contingent Value Right.
(Source: Yeko Photo Studio for freepik)
Through this acquisition, Sun Pharma intends to deepen its presence in the skin cancer segment; Sun Pharma’s existing portfolio in this space includes Levulan and Odomzo, having filed Nidlegy for melanoma.
